Human Development

Adult immunizations: routine schedule by age and condition

Clinical Overview and When to Suspect Immunization Gaps

— New patient intake, annual wellness visit, Medicare AWV

— Pre-travel, pre-pregnancy, pre-chemotherapy/biologic, pre-splenectomy, pre-transplant

— New diagnosis of diabetes, CKD, HIV, asplenia, immunosuppression

— Occupational exposure (healthcare worker, lab) or outbreak setting

— Hospital discharge — especially pneumococcal, influenza, Tdap

— Age (≥19, ≥50, ≥65)

— Pregnancy status

— Medical conditions (immunocompromise, asplenia, CKD, CSF leak/cochlear implant, chronic heart/lung/liver disease, diabetes)

— Occupation/lifestyle (HCW, MSM, IDU, travel)

— Prior vaccination history — verify with records, not patient recall alone

— Live attenuated: MMR, varicella, zoster (live ZVL — now rarely used), LAIV, yellow fever, oral typhoid, BCG, rotavirus, smallpox

— Contraindicated in pregnancy and significant immunocompromise (CD4 <200, high-dose steroids ≥20 mg prednisone ≥14 days, biologics, active chemo)

— Inactivated/recombinant/toxoid/mRNA vaccines: generally safe in immunocompromise (though may be less immunogenic)

Board pearl: The single most tested adult-immunization concept is don't give live vaccines to pregnant or significantly immunocompromised patients, and give inactivated influenza and Tdap in every pregnancy (Tdap at 27–36 weeks). Anchor every stem to those two rules first.

Definition and scope: Adult immunization is a longitudinal, age- and condition-stratified preventive service guided by the ACIP/CDC schedule, updated annually. On Step 3, expect outpatient stems asking which vaccine to give today, what to defer, and how to document/recall.

Why it matters: Vaccine-preventable diseases (influenza, pneumococcal disease, herpes zoster, HPV-related cancers, pertussis) cause substantial adult morbidity. Adult coverage rates lag pediatric rates — closing gaps is a quality metric (HEDIS, MIPS).

When to "suspect" a gap (every visit):

Framework for the exam (5 axes):

Live vs inactivated distinction drives most tricky questions:

Presentation Patterns and Key History

— "A 67-year-old presents for annual exam…"

— "A 28-year-old at 30 weeks gestation comes for routine prenatal care…"

— "A 45-year-old with newly diagnosed HIV (CD4 350)…"

— "A patient is about to start rituximab/anti-TNF/chemotherapy…"

— Discharge planning after splenectomy, cochlear implant, or transplant evaluation

— Age in years (drives Tdap/Td, zoster, pneumococcal, RSV)

— Pregnancy and gestational age (Tdap 27–36 wk; influenza any trimester; RSV maternal 32–36 wk Sept–Jan; avoid live)

— Chronic conditions: DM, CKD, CHF, COPD, cirrhosis, asplenia (functional from sickle cell counts), CSF leak, cochlear implant

— Immunocompromise: HIV with CD4 count, solid organ or HSCT, active malignancy, B-cell depleters, steroids dose/duration

— Sexual history and substance use: HPV, hepatitis A/B, mpox indications

— Occupation: HCW (HepB, MMR, varicella, influenza, Tdap), lab workers, public safety

— Travel: destination-specific (yellow fever, typhoid, HepA, Japanese encephalitis, meningococcal for Hajj)

— Household contacts: infants <12 mo (cocooning Tdap, influenza), immunocompromised contacts (avoid LAIV in caregiver)

— Allergies: anaphylaxis to prior dose or component (egg allergy is not a contraindication to most flu vaccines now)

— Patient recall of "I had all my shots" is unreliable — request records or check state IIS registry

— If records unavailable for MMR/varicella in adults born ≥1957, check titers or simply revaccinate (no harm)

Step 3 management: At every adult encounter, do a 30-second vaccine review: age-based (flu, Tdap/Td, zoster ≥50, pneumococcal ≥50, RSV ≥75 or 60–74 high-risk), condition-based (HepB if DM <60, PPSV/PCV if asplenic), and risk-based (HPV through 26, shared decision 27–45). Documenting the offer — even if declined — protects against quality-metric and liability concerns.

Typical Step 3 stems open with an outpatient visit:

High-yield history elements to extract:

Documentation pitfalls:

Physical Exam Findings and Pre-Vaccination Assessment

— Moderate-to-severe acute illness with or without fever → defer vaccination until improved

— Mild illness (URI, low-grade fever, diarrhea) → not a contraindication; proceed

— Stable chronic disease is never a contraindication

— Confirm gestational age; document LMP

— Live vaccines contraindicated; counsel to avoid pregnancy for 4 weeks after MMR or varicella

— Splenectomy scar (LUQ), sickle cell stigmata → functional asplenia workup

— Cushingoid features, chronic steroid use

— Lymphadenopathy, oral thrush, wasting → consider HIV testing before live vaccines

— Cochlear implant or CSF leak history (post-trauma rhinorrhea) → pneumococcal indication regardless of age

— Deltoid IM for most adult vaccines; 1–1.5 inch needle

— Subcutaneous for MMR, varicella, zoster (RZV is IM), meningococcal B in some

— Separate sites if multiple vaccines same day; no maximum number of simultaneous vaccines

— Ask about anaphylaxis to prior dose or component (gelatin, neomycin, yeast for HepB, latex)

— Egg-allergic patients can receive any flu vaccine (cell-based or recombinant if severe history; standard IIV acceptable per ACIP 2023 update)

— Have epinephrine available; observe 15 minutes after any vaccine (30 min if prior allergic reaction)

Key distinction: True contraindication (anaphylaxis to component, encephalopathy within 7 days of pertussis vaccine for DTaP) vs precaution (moderate/severe illness, Guillain-Barré within 6 weeks of prior flu vaccine, pregnancy for live vaccines, recent antibody products delaying live vaccines). Precautions allow vaccination when benefit outweighs risk; contraindications do not. Mixing these up is a classic distractor on the exam.

Vaccines are a clinic-flow decision, not an exam-finding diagnosis — but Step 3 does test the pre-vaccination assessment:

Vital signs and acute illness screen:

Pregnancy assessment:

Immune status exam clues:

Injection site and technique:

Allergy assessment:

Diagnostic Workup — Serologies, Titers, and Pre-Vaccine Labs

— HCWs and students entering training: MMR, varicella, HepB anti-HBs

— Pregnancy panel: rubella IgG, varicella IgG, HBsAg, HIV — vaccinate post-partum for non-immune rubella/varicella

— Pre-transplant or pre-immunosuppression: measles, mumps, rubella, varicella, HepA, HepB serologies; complete needed live vaccines ≥4 weeks before immunosuppression

— HepB post-vaccination titer (anti-HBs): HCWs, hemodialysis patients, infants of HBsAg+ mothers, immunocompromised, sexual partners of HBsAg+; check 1–2 months after series

— Anti-HBs ≥10 mIU/mL = immune; <10 = revaccinate with second series, then retest

— CD4 ≥200 (≥15%): MMR and varicella generally permitted

— CD4 <200: avoid live vaccines

— MMR can transiently suppress TST/IGRA reactivity

— Either place TST/IGRA same day as MMR or wait ≥4 weeks after MMR

— IVIG, blood products → delay MMR/varicella 3–11 months depending on product

— Live vaccines given ≥2 weeks before antibody product are OK

Board pearl: Anti-HBs <10 mIU/mL after a full HepB series → repeat 3-dose series, then retest. If still <10 after two complete series, the patient is a non-responder; counsel about HBIG post-exposure rather than further vaccination. This is a frequent CCS-style outpatient follow-up question.

When to check titers before vaccinating (limited but high-yield):

HIV testing before live vaccines: indicated if risk factors and unknown status; CD4 count guides MMR/VZV/zoster decisions

Pneumococcal — no titer needed; decisions are clinical

Routine labs are NOT required before influenza, Tdap, HPV, pneumococcal, zoster (RZV), COVID, RSV in immunocompetent adults

Tuberculin testing and MMR:

Antibody products and live vaccines:

Diagnostic Workup — Verifying Immunity and Special Testing

— Measles/mumps/rubella: written record of age-appropriate vaccination, lab evidence of immunity, lab confirmation of disease, or birth before 1957 (presumed immune except HCWs)

— Varicella: 2-dose vaccination, lab evidence, HCP-diagnosed disease/zoster, or birth in US before 1980 (except HCWs, pregnant women, immunocompromised — these need lab evidence)

— HepB: documented 2- or 3-dose series, or anti-HBs ≥10

— Document which product (PCV13, PCV15, PCV20, PCV21, PPSV23) and date — drives next step

— 2024 ACIP simplified schedule: adults ≥50 (lowered from 65) → single dose PCV20 or PCV21, OR PCV15 followed by PPSV23 ≥1 year later (8 weeks if immunocompromised/asplenia/CSF leak/cochlear implant)

— 2 doses 2–6 months apart for adults ≥50, and ≥19 if immunocompromised

— No titer needed; give regardless of prior zoster episode or prior live ZVL

— Routine through age 26; shared clinical decision-making 27–45

— 2 doses if started before 15th birthday; 3 doses if started ≥15 or immunocompromised

— Yellow fever requires International Certificate of Vaccination (yellow card), only at designated centers

— Rabies pre-exposure: titer monitoring for ongoing-risk personnel

— Asplenia: confirm with Howell-Jolly bodies on smear if uncertain; functional asplenia (sickle cell, post-splenectomy) carries same indications

Step 3 management: When pneumococcal history is unclear or undocumented, the simplest correct answer is to give a single dose of PCV20 (or PCV21) — this satisfies the ACIP recommendation without needing prior records. This "one-and-done" option is the most commonly tested 2024–2025 update.

Documentation of immunity (acceptable evidence):

Pneumococcal status verification:

Zoster (RZV, Shingrix):

HPV:

Travel-specific testing:

Special population confirmation:

Risk Stratification and Schedule Logic by Age

— Annual: Influenza (any age ≥6 months); COVID-19 per current ACIP (≥1 dose of updated formulation annually for most)

— Every 10 years: Td or Tdap booster; substitute Tdap for one booster if not previously received

— Each pregnancy: Tdap at 27–36 weeks

— HepB: universal recommendation ages 19–59; ≥60 if risk factors or shared decision-making

— HPV: routine through 26; SDM 27–45

— MenACWY/MenB: college freshmen in dorms, military, complement deficiency, asplenia, HIV, microbiologists, travel to meningitis belt

— Zoster (RZV): 2 doses

— Pneumococcal: PCV20 ×1 or PCV15→PPSV23 (per 2024 update lowering age from 65 to 50)

— RSV vaccine: shared decision-making 60–74 with risk factors; routine ≥75 (per 2024 update)

— High-dose or adjuvanted influenza preferred (Fluzone HD, Flublok, Fluad)

— Diabetes: HepB if <60; routine if ≥60 with risk

— Asplenia/complement deficiency: PCV + PPSV23, MenACWY (2 doses + booster q5y), MenB, Hib (asplenia)

— CKD/dialysis: HepB (higher dose), pneumococcal

— Chronic liver disease: HepA, HepB, pneumococcal

— Immunocompromise: RZV from age 19, pneumococcal, no live vaccines

Board pearl: Memorize the "50 milestone" — at age 50 in 2024+, adults newly qualify for zoster (RZV) and pneumococcal (PCV20). The lowered pneumococcal threshold from 65 → 50 is among the most testable recent ACIP changes.

Age-based core schedule (all adults, immunocompetent, no special conditions):

Age ≥19 with risk factors only:

Age ≥50:

Age ≥60:

Age ≥65:

Condition-driven additions (any age):

Pharmacotherapy — Vaccine-by-Vaccine Regimens

— IIV4, RIV4 (Flublok, recombinant), ccIIV4 (cell-based), LAIV4 (intranasal, ages 2–49, healthy non-pregnant)

— ≥65: prefer HD-IIV, adjuvanted, or recombinant

— Egg allergy: any vaccine acceptable

— Tdap once in adulthood, then Td or Tdap every 10 years

— Tdap every pregnancy (27–36 weeks)

— Tetanus-prone wound: Tdap if not had within 5 years; TIG if <3 prior tetanus doses and dirty wound

— PCV20 ×1 OR PCV21 ×1 OR PCV15 → PPSV23 (≥1 yr later; 8 wk if immunocompromised)

— Indications: ≥50, or 19–49 with chronic conditions/immunocompromise/asplenia/CSF leak/cochlear implant

— 2 doses IM, 2–6 months apart

— ≥50 routine; ≥19 if immunocompromised (interval can shorten to 1–2 months)

— 2 doses (0, 6–12 mo) if <15; 3 doses (0, 1–2, 6 mo) if ≥15 or immunocompromised

— Through age 26 routine; 27–45 SDM

— 2-dose Heplisav-B (0, 1 mo) or 3-dose Engerix/Recombivax (0, 1, 6 mo)

— Dialysis: higher dose formulation

Step 3 management: The most common Tdap stem is a pregnant patient at 28–32 weeks — give Tdap regardless of prior dose; the goal is transplacental antibody transfer to protect the newborn from pertussis.

Influenza (annual):

Tdap/Td:

Pneumococcal:

Zoster (RZV, Shingrix):

HPV (Gardasil 9):

HepB:

HepA: 2 doses 6 months apart; or HepA/HepB combo (Twinrix) 3 doses

MMR: 1 dose adults; 2 doses for HCW, students, travelers, post-exposure

Varicella: 2 doses 4–8 weeks apart for non-immune adults

MenACWY: primary + booster q5y if ongoing risk

MenB: 2-dose (Bexsero 0, ≥1 mo) or 3-dose (Trumenba 0, 1–2, 6 mo); same brand throughout

RSV: single dose of RSVPreF3 (Arexvy), RSVPreF (Abrysvo), or mRNA-1345 (mResvia); no annual revaccination yet

COVID-19: annual updated formulation per current ACIP

Special Vaccination Scenarios — Timing, Sequencing, Combinations

— Give ≥4 weeks before initiating immunosuppression

— After stopping: wait ≥1 month (low-dose steroids), ≥3 months (chemo/high-dose steroids), ≥6 months (rituximab/B-cell depleters)

— Poor response; ideally vaccinate ≥2 weeks before, or wait ≥6 months after last dose for optimal response

— Complete PCV, PPSV23, MenACWY, MenB, Hib ≥2 weeks before surgery if possible

— Post-emergent splenectomy: vaccinate ≥14 days post-op

— Complete all live vaccines ≥4 weeks before transplant

— Post-HSCT: revaccinate full pediatric-style series starting 6–12 months post-transplant

— HepB: HBIG + vaccine series if unvaccinated, exposed to HBsAg+

— Rabies: wound care + RIG + 4-dose vaccine series (unvaccinated); 2 doses + no RIG (previously vaccinated)

— Tetanus-prone wound: Tdap ± TIG

— Measles: MMR within 72 hrs of exposure, or IG within 6 days

— Varicella: vaccine within 3–5 days; VZIG for immunocompromised, pregnant, neonates

CCS pearl: For a planned splenectomy (e.g., hereditary spherocytosis, ITP), order PCV20, MenACWY, MenB, and Hib at least 2 weeks before surgery. On CCS, advance the clock to allow the 2-week window and document each vaccine; missing this is a common quality-of-care deduction.

Multiple vaccines same day: Always acceptable; use separate sites. No minimum interval between inactivated vaccines. Between two live parenteral vaccines: give same day OR space ≥28 days apart (otherwise repeat the second).

Live vaccine and immunosuppression:

Anti-CD20 (rituximab) and inactivated vaccines:

Asplenia (planned splenectomy):

Pre-transplant (solid organ or HSCT):

Post-exposure prophylaxis:

Travel vaccines: yellow fever (≥10 days before travel), typhoid, Japanese encephalitis, cholera, rabies pre-exposure

Mpox (JYNNEOS): 2 doses 4 weeks apart for high-risk MSM, certain occupational exposures

Special Populations — Elderly and Renal/Hepatic Impairment

— High-dose IIV (Fluzone HD), adjuvanted IIV (Fluad), recombinant (Flublok) > standard IIV

— If preferred not available, give standard IIV — don't delay

— Already covered by lowered age threshold (50); ensure single PCV20/21 dose or PCV15→PPSV23 completed

— If previously vaccinated only with PPSV23, give PCV20 ≥1 year later

— HepB: higher antigen dose (e.g., Engerix-B 40 mcg) or Heplisav-B; check post-vaccination anti-HBs; revaccinate if <10

— Pneumococcal: indicated at any age with CKD

— Influenza: annual, standard or enhanced

— Avoid LAIV (live)

— HepA and HepB strongly indicated

— Pneumococcal indicated

— Avoid LAIV if decompensated; otherwise live vaccines case-by-case

— Frailty is not a contraindication; benefits clearest in this group for flu, pneumococcal, RSV, zoster

— Coordinate with home health, pharmacy-based vaccination for housebound patients

Board pearl: A dialysis patient with anti-HBs <10 after a full HepB series should receive a second complete series with the higher-dose dialysis formulation (or Heplisav-B) and retesting in 1–2 months. Don't simply give a single booster.

Adults ≥65 — enhanced influenza formulations preferred:

Pneumococcal in ≥65:

RSV in ≥75: routine single dose; in 60–74 with chronic heart/lung disease, DM, CKD, immunocompromise — shared decision-making (formerly required, now permissive)

Zoster: 2-dose RZV regardless of prior episode; very high efficacy maintained in elderly

Chronic kidney disease and dialysis:

Chronic liver disease (cirrhosis, chronic HCV, NAFLD with fibrosis):

Functional considerations in elderly:

Polypharmacy: vaccines do not interact pharmacokinetically with most chronic medications; warfarin patients can receive IM injections with small-gauge needle and post-injection pressure

Special Populations — Pregnancy, Postpartum, and Immunocompromised

— Influenza (inactivated) — any trimester, every pregnancy

— Tdap — every pregnancy at 27–36 weeks (earlier in this window is better for antibody transfer)

— COVID-19 — per current ACIP

— RSV (RSVPreF, Abrysvo) — single dose at 32–36 weeks during September–January (alternative is infant nirsevimab)

— HepB, HepA, pneumococcal, MenACWY/MenB — if indicated by risk

— MMR, varicella, LAIV, zoster, yellow fever (unless travel unavoidable), HPV (not contraindicated but defer to postpartum)

— Counsel avoidance of pregnancy for 4 weeks after MMR/varicella

— Give non-immune rubella and varicella vaccines before discharge; breastfeeding is not a contraindication to any vaccine (except smallpox)

— Tdap for partners and household contacts of newborn (cocooning)

— CD4 ≥200: MMR and varicella allowed; all routine inactivated vaccines

— CD4 <200: no live vaccines; give inactivated (may have reduced response — reassess after immune reconstitution)

— Pneumococcal, HepA, HepB, HPV through 26 (consider through 45), zoster RZV, meningococcal indicated

— Complete vaccinations pre-transplant/pre-treatment when possible

— No live vaccines after transplant

— Annual flu (inactivated), pneumococcal, HepB, RZV (recombinant — safe), COVID-19

— PCV + PPSV23, MenACWY (2-dose + booster q5y), MenB, Hib

Step 3 management: The single most-tested pregnancy stem is "30 weeks gestation, last Tdap was 4 years ago — what do you do?" Answer: Give Tdap now, regardless of prior interval, because the recommendation is per-pregnancy.

Pregnancy — give these:

Pregnancy — avoid (live vaccines):

Postpartum:

HIV:

Solid organ transplant / chemotherapy / biologics:

Asplenia and complement deficiency:

Complications and Adverse Outcomes

— Local: pain, erythema, swelling at injection site (most common with RZV, Tdap)

— Systemic: low-grade fever, myalgia, fatigue, headache — usually 24–48 hours

— Counsel and pre-medicate after if needed; routine prophylactic acetaminophen may blunt immune response (debated; not recommended pre-vaccination)

— Anaphylaxis: any vaccine, ~1 per million; treat with IM epinephrine 0.3–0.5 mg, observe, report

— Guillain-Barré syndrome: historical association with 1976 swine flu vaccine; small absolute risk increase with current flu vaccines (~1/million); prior GBS within 6 weeks of flu vaccine is a precaution (not absolute contraindication)

— Thrombosis with thrombocytopenia syndrome (TTS): associated with adenovirus-vector COVID vaccines (J&J — no longer used in US)

— Myocarditis/pericarditis: mRNA COVID vaccines, especially young males after dose 2; usually mild, self-limited

— Shoulder injury related to vaccine administration (SIRVA): from injection too high in deltoid into bursa

— Syncope: especially adolescents post-HPV/MenACWY; observe seated 15 minutes

— VAERS (Vaccine Adverse Event Reporting System) — passive, anyone can report

— VSD (Vaccine Safety Datalink) — active surveillance

— NVICP (National Vaccine Injury Compensation Program) — no-fault compensation for table injuries

— Confirm immune status (anti-HBs after HepB series in high-risk groups)

— Consider revaccination per ACIP rather than declaring true non-response prematurely

— Counsel; outcomes generally good

— Not an indication for pregnancy termination

Board pearl: Post-vaccine syncope is a fall/injury risk — keep adolescents and anxious patients seated and observed for 15 minutes after HPV, MenACWY, and Tdap. This is a patient-safety question that recurs frequently.

Common, mild, expected:

Serious, rare adverse events to recognize:

Reporting:

Vaccine failure / breakthrough:

Live vaccine inadvertently given in pregnancy or immunocompromise:

When to Escalate Care — Reactions, Outbreaks, and Specialty Consultation

— Anaphylaxis: IM epinephrine first (do not delay for IV access), 911/transfer for observation, H1/H2 blockers and steroids adjunctive

— Vasovagal syncope: supine, legs elevated, monitor — distinguish from anaphylaxis (syncope: pallor, bradycardia, brief, no urticaria/wheeze)

— Document, report to VAERS

— Severe reaction to prior dose of a needed vaccine

— Multiple vaccine component allergies

— Skin testing or graded challenge protocols for high-priority vaccines (e.g., MMR in severe egg allergy — though usually not needed)

— Complex immunocompromised patients (post-HSCT, multi-agent biologics)

— Pre-transplant vaccination planning

— International travel with complex destinations

— Suspected vaccine failure with active disease (HepB breakthrough, etc.)

— Vaccine-preventable disease cases (measles, mumps, pertussis, meningococcal disease, hepatitis A, varicella in outbreaks) — reportable

— Health department coordinates post-exposure prophylaxis for contacts

— Measles exposure: identify susceptible contacts, give MMR within 72 hrs or IG within 6 days

— Hepatitis A community outbreak: vaccinate susceptible adults

— Pertussis: antibiotic prophylaxis for close contacts plus Tdap if not current

— Severe anaphylaxis with airway involvement

— Suspected GBS post-vaccination (ascending weakness, areflexia) — admit for neurologic workup, IVIG/plasmapheresis

CCS pearl: If a CCS case opens with measles exposure in a clinic, the immediate actions are: isolate the index case (airborne precautions), identify contacts, check immunization records, give MMR within 72 hours to susceptible non-pregnant immunocompetent contacts, IG within 6 days for pregnant/immunocompromised, and notify public health. All five count for credit.

Acute vaccine reaction in clinic:

Allergy/Immunology referral indications:

Infectious disease consultation:

Public health notification:

Outbreak management:

Hospital admission considerations (rare from vaccines themselves):

Key Differentials — Distinguishing Similar Vaccines and Indications

— PCV13/15/20/21: conjugate, T-cell-dependent, better memory response

— PPSV23: polysaccharide, T-cell-independent, broader serotype coverage but weaker memory

— 2024 simplified: PCV20 or PCV21 alone is sufficient; PCV15 must be followed by PPSV23

— Don't give PCV and PPSV23 same day; space ≥1 year (8 wk if immunocompromised/asplenia)

— Tdap: contains pertussis; use in pregnancy, wound care if pertussis booster needed, and as the once-in-adulthood pertussis booster

— Td: tetanus-diphtheria only; acceptable for routine 10-year boosters after first adult Tdap

— Either is acceptable for routine boosters now

— IIV (standard), HD-IIV (≥65), adjuvanted (Fluad, ≥65), RIV (recombinant, egg-free), ccIIV (cell-based), LAIV (live intranasal, ages 2–49, healthy)

— LAIV contraindicated in pregnancy, immunocompromise, asplenia, age <2 or ≥50, asthma in 2–4 yo

— RZV (Shingrix): recombinant, 2 doses, current standard, safe in immunocompromised

— ZVL (Zostavax): live, no longer available in US

— Give RZV even if prior ZVL or prior zoster episode

— MenACWY (Menveo, Menactra, MenQuadfi): serogroups A, C, W, Y

— MenB (Bexsero, Trumenba): serogroup B

— Pentavalent MenABCWY (Penbraya, Penmenvy): newer, single product covers all five

— Different indications: adolescents get MenACWY routinely; MenB by SDM ages 16–23 or risk-based

— Twinrix = HepA + HepB combo, 3-dose

Key distinction: PCV is conjugate (T-cell memory), PPSV23 is polysaccharide (no memory). Give conjugate first when both are needed, then polysaccharide later, because PPSV23 first blunts the response to subsequent PCV.

Pneumococcal product confusion (highest-yield differential):

Tdap vs Td:

Influenza products:

Zoster:

Meningococcal:

HepA, HepB, and combinations:

Key Differentials — Conditions That Mimic Vaccine Indications or Reactions

— "Allergy" to penicillin or sulfa: irrelevant to vaccine eligibility

— "Egg allergy": no longer a contraindication or precaution to flu vaccines (2023 ACIP update); any age-appropriate flu vaccine can be given

— "Family history of vaccine reaction": not a contraindication

— "Immunosuppression in a household contact": does not contraindicate inactivated vaccines in patient; only LAIV and oral polio are restricted (avoid LAIV if household contact is severely immunocompromised)

— Breastfeeding: not a contraindication to any vaccine (except smallpox)

— Vasovagal syncope (especially adolescents): bradycardia, pallor, brief loss of consciousness, no urticaria — supportive care

— Anxiety/hyperventilation: tachycardia, paresthesias, no urticaria or hypotension

— True anaphylaxis: urticaria, angioedema, wheeze, hypotension, GI symptoms — epinephrine

— Post-vaccine arm soreness vs cellulitis: localized redness within 48h is expected; spreading erythema, fever, lymphangitis after 72h suggests cellulitis

— Bell's palsy: rare temporal association; not causally linked

— Autism: no causal link with MMR; counsel families; don't withhold vaccines

— History of GBS within 6 weeks of flu vaccine: precaution; weigh risk

— History of intussusception: contraindication to rotavirus (pediatric, not adult)

— Severe combined immunodeficiency: contraindication to live vaccines

— Moderate/severe acute illness

— Recent receipt of antibody-containing product (delays live vaccines 3–11 months)

— Recent live vaccine (delays another live vaccine 28 days)

Board pearl: When the stem says "egg allergy" or "household member is immunocompromised," these are usually distractors, not contraindications. Give the vaccine.

Conditions that look like a vaccine indication but aren't:

Reactions that mimic anaphylaxis:

Conditions confused with vaccine adverse events:

Conditions that change vaccine choice but not eligibility:

Conditions that may delay (not cancel) vaccination:

Long-Term Plan, Catch-Up Schedules, and Secondary Prevention

— Review CDC adult immunization schedule for updates

— Re-screen all 5 axes (age, pregnancy, conditions, occupation, travel)

— Document declines with reason

— Adults with no records: assume unvaccinated, start age-appropriate schedule; serologies only when they change management (MMR/varicella for HCWs, HepB titers)

— Interrupted series: resume where left off — do not restart (HepB, HPV, RZV, MenB)

— MMR/varicella as adults: 1 dose MMR (2 for HCW/students/travelers); 2 doses varicella 4–8 wk apart

— Pharmacy and nurse-driven standing orders increase coverage

— EHR pop-up reminders and patient portal outreach

— State Immunization Information Systems (IIS) for record-sharing

— HEDIS: adult flu, pneumococcal, zoster, Tdap

— Medicare Star Ratings, MIPS — billing for vaccine administration (CPT 90471, 90460 series)

— Use presumptive language: "You're due for your flu shot today"

— Motivational interviewing for refusers

— Acknowledge concerns, share evidence, revisit at next visit

— Don't dismiss patients from practice for declining (AAP/AAFP guidance varies)

— Travel: re-evaluate before each international trip

— Occupational changes: HCW transition triggers MMR, varicella, HepB, Tdap, flu requirements

— Pregnancy planning: complete live vaccines before conception

— Aging milestones: 50 (RZV, pneumococcal), 65 (HD flu), 75 (RSV)

Step 3 management: For vaccine hesitancy, the best initial response is explore concerns with open-ended questions and motivational interviewing, not immediate dismissal or detailed statistics. Build trust, revisit at next visit, and document the offer/refusal.

Annual reset (every January / each patient's birthday or AWV):

Catch-up logic:

Standing orders and EHR best practices:

Quality metrics tied to adult immunization:

Counseling for vaccine hesitancy:

Special long-term considerations:

Follow-Up, Monitoring Parameters, and Patient Counseling

— Most vaccines: no specific follow-up needed beyond next scheduled visit

— Counsel about expected local/systemic reactions for 24–48 hrs

— Acetaminophen or NSAIDs for symptomatic relief after symptoms develop

— Anti-HBs 1–2 months after HepB series in HCWs, dialysis, infants of HBsAg+ mothers, immunocompromised, sexual partners of HBsAg+

— Rabies pre-exposure: titer monitoring for ongoing-risk personnel (every 6 months to 2 years)

— No routine post-vaccine titers for MMR, varicella, pneumococcal, flu, Tdap, HPV, RZV

— HPV: 2 or 3 doses depending on age at start

— HepB: 2 (Heplisav-B) or 3 doses

— RZV: 2 doses, 2–6 months apart

— MenB: 2 or 3 doses (same brand)

— Use EHR recall, patient portal reminders, pharmacy outreach

— What the vaccine prevents

— When to expect the next dose / next vaccine

— Side effects: expected vs concerning

— Where to get records (patient portal, IIS, vaccine card)

— Don't co-administer live vaccines with planned pregnancy in next 4 weeks

— Vaccine name, lot number, manufacturer, date, site, route

— Vaccine Information Statement (VIS) given — date of VIS

— Vaccinator's name and title

— Yellow fever certificate valid for life (per WHO since 2016)

— Rabies series completion if exposure occurred while traveling

Board pearl: Under the National Childhood Vaccine Injury Act (NCVIA) — which despite its name applies to all routine vaccines, adults included — you must provide the current VIS before administration and document it. Failure to do so is a common patient-safety/legal pitfall.

Routine follow-up after vaccination:

Post-vaccination serology — selective:

Series completion tracking:

Patient counseling priorities:

Documentation requirements (NCVIA):

Travel follow-up:

Ethical, Legal, and Patient Safety Considerations

— Patients have the right to refuse vaccines after appropriate counseling

— Document the offer, the discussion of benefits/risks, and the refusal

— For minors and adolescents (HPV, MenACWY): parental consent required in most states, though some states allow minor consent for STI-related vaccines (HPV in some jurisdictions)

— VAERS for serious adverse events, deaths, events listed in the Reportable Events Table within specified intervals

— Vaccine-preventable diseases (measles, mumps, pertussis, meningococcal, HepA, varicella outbreaks) are reportable to public health

— No-fault federal program for table injuries (e.g., anaphylaxis within 4 hrs, SIRVA, GBS after flu vaccine within 42 days)

— Patients/families file with US Court of Federal Claims; lawsuits against manufacturers/providers preempted for covered vaccines

— Hospitals may require flu, MMR, varicella, Tdap, HepB as condition of employment (OSHA, CMS conditions of participation)

— Religious/medical exemptions vary by employer and state

— Hospital discharge is a high-risk handoff for missed vaccinations

— Pneumococcal and influenza standing orders at discharge reduce readmissions for pneumonia

— Communicate vaccines given/needed in discharge summary to PCP

— Vaccines for Children program covers pediatric uninsured

— Section 317 funds for uninsured adults (limited)

— ACA preventive services: most routine adult vaccines covered with no cost-sharing

— Medicare Part D covers most adult vaccines (since 2023 IRA expansion — no cost-sharing for ACIP-recommended vaccines)

Step 3 management: A patient declining their child's vaccines — don't dismiss from practice as a first step; engage with motivational interviewing, document refusal, and continue care. Mandatory reporting still applies for suspected vaccine-preventable disease, not for refusal itself.

Informed consent and refusal:

Mandatory reporting:

Vaccine Injury Compensation Program (VICP):

Occupational health and HCW vaccination:

Transition-of-care risk (Step 3 flavor):

Equity and access:

Cultural competency: address religious concerns (gelatin, porcine ingredients) — alternative products often available

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: When in doubt and history is uncertain, give a single dose of PCV20 for pneumococcal — it's the simplest right answer for adults ≥50 or younger with indications.

Pregnancy "TIRC": Tdap (27–36 wk), Influenza (any trimester), RSV (32–36 wk, Sept–Jan), COVID-19

No live vaccines in pregnancy — MMR, varicella, LAIV, zoster, yellow fever

CD4 ≥200 in HIV: MMR and varicella OK; <200: no live vaccines

Age 50 milestone: RZV (zoster) and pneumococcal (lowered from 65)

Age ≥75: routine RSV

Age ≥65: prefer high-dose / adjuvanted / recombinant flu vaccine

HPV: routine through 26; SDM 27–45; 2 doses if <15, 3 doses if ≥15 or immunocompromised

HepB: universal 19–59; ≥60 with risk factors or SDM

Asplenia (functional or surgical): PCV20, PPSV23, MenACWY (+booster q5y), MenB, Hib — 2 weeks before planned splenectomy

CSF leak or cochlear implant: pneumococcal indicated regardless of age

Tetanus-prone wound + last Tdap <5 years: no booster needed; 5–10 years: Tdap; unknown/<3 doses + dirty wound: Tdap + TIG

Egg allergy: NOT a contraindication to any flu vaccine

GBS within 6 weeks of flu vaccine: precaution, not absolute contraindication

Multiple live vaccines: same day OR ≥28 days apart

MMR and TST/IGRA: same day or wait 4 weeks

IVIG/blood products and MMR/varicella: delay 3–11 months

Rituximab and inactivated vaccines: vaccinate ≥2 wk before or wait 6 mo after

HepB non-responder after 2 series: rely on HBIG post-exposure

Splenectomy emergent: wait ≥14 days post-op to vaccinate

Yellow fever: only at designated centers, certificate, ≥10 days before travel

VAERS: any adverse event; VICP: compensation for table injuries

Post-vaccine syncope: observe seated 15 minutes (adolescents especially)

SIRVA: inject deltoid, not too high (avoid bursa)

Board Question Stem Patterns

— Always: Tdap (regardless of prior interval) + influenza (inactivated) + RSV if Sept–Jan

— Never: MMR, varicella, LAIV

— Give: pneumococcal (PCV20), HepB (if not immune), HepA, HPV (through 26, consider through 45), RZV, annual flu, Tdap, MenACWY + MenB

— Live (MMR, varicella) OK since CD4 ≥200

— PCV20, MenACWY (+booster q5y), MenB, Hib ≥2 weeks before elective surgery; 14 days after emergent

— MMR (2 doses or titer), varicella (2 doses or titer), HepB (series + anti-HBs ≥10), Tdap, annual flu

— Clean minor + <10 yr since Td/Tdap → no booster

— Dirty wound + <5 yr → no booster

— Dirty wound + ≥5 yr or unknown → Tdap; TIG if <3 prior doses

— Give PCV20 single dose

— Born <1957: presumed immune to measles/mumps/rubella (except HCW)

— Born ≥1957: give MMR (1 or 2 doses by setting)

— Allergy/immunology referral; consider alternative product or graded administration; absolute contraindication only if anaphylaxis to specific component

— Give inactivated flu vaccine ≥2 weeks before next rituximab dose, or wait ≥6 months after; no live vaccines

— Counsel on age-related risk of YEL-AVD (viscerotropic disease); medical waiver if not essential; otherwise vaccinate with informed consent at designated center

Step 3 management: When stems give multiple vaccine options on the same day, the correct answer is almost always "administer all indicated vaccines today at separate sites" — there is no benefit to delaying or sequencing inactivated vaccines.

Pattern 1 — Pregnant patient at 28–32 weeks:

Pattern 2 — Newly diagnosed HIV, CD4 350:

Pattern 3 — Planned splenectomy or new asplenia:

Pattern 4 — Healthcare worker pre-employment:

Pattern 5 — Tetanus-prone wound:

Pattern 6 — Pneumococcal unclear history, age 60+:

Pattern 7 — Adult born 1968 with no immunization records, no symptoms:

Pattern 8 — Anaphylaxis after first flu vaccine dose:

Pattern 9 — Patient on rituximab needing flu vaccine:

Pattern 10 — Travel to yellow fever zone, age 70:

One-Line Recap

The ACIP adult immunization schedule is best mastered by stratifying every patient across five axes — age, pregnancy, medical conditions, occupation, and lifestyle/travel — then applying two unbreakable rules: avoid live vaccines in pregnancy and significant immunocompromise, and give Tdap plus inactivated influenza in every pregnancy.

Five-axis checklist at every visit: age (annual flu, Td/Tdap q10y, RZV ≥50, pneumococcal ≥50, RSV ≥75, high-dose flu ≥65); pregnancy (Tdap 27–36 wk, flu, RSV 32–36 wk Sept–Jan, COVID); conditions (HepB if DM <60, pneumococcal/MenACWY/MenB/Hib if asplenic, HepA/B if chronic liver disease, RZV from 19 if immunocompromised); occupation (HCWs need MMR, varicella, HepB, Tdap, flu); lifestyle/travel (HPV through 26 or SDM 27–45, mpox for high-risk MSM, destination-specific travel vaccines).

Live vaccine rule: MMR, varicella, LAIV, zoster (live, obsolete), yellow fever, oral typhoid — avoid in pregnancy and significant immunocompromise (CD4 <200, biologics, high-dose steroids, chemo); complete ≥4 weeks before immunosuppression starts; space multiple live vaccines ≥28 days or same day.

2024+ high-yield updates: pneumococcal age lowered to 50 (PCV20 ×1 simplest), RSV routine at ≥75 with SDM 60–74, egg allergy no longer a flu vaccine concern, Medicare Part D covers ACIP vaccines with no cost-sharing.

Patient-safety anchors: observe 15 min post-vaccination (syncope), document VIS (NCVIA), report serious events to VAERS, file VICP claims for table injuries, and never miss the discharge and prenatal visit as vaccine opportunities.